» Articles » PMID: 17804504

High Fidelity of Murine Hepatitis Virus Replication is Decreased in Nsp14 Exoribonuclease Mutants

Overview
Journal J Virol
Date 2007 Sep 7
PMID 17804504
Citations 212
Authors
Affiliations
Soon will be listed here.
Abstract

Replication fidelity of RNA virus genomes is constrained by the opposing necessities of generating sufficient diversity for adaptation and maintaining genetic stability, but it is unclear how the largest viral RNA genomes have evolved and are maintained under these constraints. A coronavirus (CoV) nonstructural protein, nsp14, contains conserved active-site motifs of cellular exonucleases, including DNA proofreading enzymes, and the severe acute respiratory syndrome CoV (SARS-CoV) nsp14 has 3'-to-5' exoribonuclease (ExoN) activity in vitro. Here, we show that nsp14 ExoN remarkably increases replication fidelity of the CoV murine hepatitis virus (MHV). Replacement of conserved MHV ExoN active-site residues with alanines resulted in viable mutant viruses with growth and RNA synthesis defects that during passage accumulated 15-fold more mutations than wild-type virus without changes in growth fitness. The estimated mutation rate for ExoN mutants was similar to that reported for other RNA viruses, whereas that of wild-type MHV was less than the established rates for RNA viruses in general, suggesting that CoVs with intact ExoN replicate with unusually high fidelity. Our results indicate that nsp14 ExoN plays a critical role in prevention or repair of nucleotide incorporation errors during genome replication. The established mutants are unique tools to test the hypothesis that high replication fidelity is required for the evolution and stability of large RNA genomes.

Citing Articles

A Comparison of Conserved Features in the Human Coronavirus Family Shows That Studies of Viruses Less Pathogenic than SARS-CoV-2, Such as HCoV-OC43, Are Good Model Systems for Elucidating Basic Mechanisms of Infection and Replication in Standard....

Heffner A, Rouault T Viruses. 2025; 17(2).

PMID: 40007010 PMC: 11860170. DOI: 10.3390/v17020256.


Structural and Phylogenetic Analysis on the Proofreading Activity of SARS-CoV-2.

Ghosh S, Biswas S, Mohanty R, Misra N, Suar M, Kushwaha G Curr Microbiol. 2025; 82(4):149.

PMID: 39992393 DOI: 10.1007/s00284-025-04130-3.


The coronavirus nsp14 exoribonuclease interface with the cofactor nsp10 is essential for efficient virus replication and enzymatic activity.

Grimes S, Heaton B, Anderson M, Burke K, Stevens L, Lu X J Virol. 2025; 99(2):e0170824.

PMID: 39791922 PMC: 11852845. DOI: 10.1128/jvi.01708-24.


Transcription Kinetics in the Coronavirus Life Cycle.

Grelewska-Nowotko K, Elhag A, Turowski T Wiley Interdiscip Rev RNA. 2025; 16(1):e70000.

PMID: 39757745 PMC: 11701415. DOI: 10.1002/wrna.70000.


SARS-CoV-2 Nsp14 binds Tollip and activates pro-inflammatory pathways while downregulating interferon-α and interferon-γ receptors.

Thakur N, Chakraborty P, Tufariello J, Basler C bioRxiv. 2024; .

PMID: 39713296 PMC: 11661139. DOI: 10.1101/2024.12.12.628214.


References
1.
Bernad A, Blanco L, Lazaro J, Martin G, Salas M . A conserved 3'----5' exonuclease active site in prokaryotic and eukaryotic DNA polymerases. Cell. 1989; 59(1):219-28. DOI: 10.1016/0092-8674(89)90883-0. View

2.
Imbert I, Guillemot J, Bourhis J, Bussetta C, Coutard B, Egloff M . A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus. EMBO J. 2006; 25(20):4933-42. PMC: 1618104. DOI: 10.1038/sj.emboj.7601368. View

3.
Seybert A, Hegyi A, Siddell S, Ziebuhr J . The human coronavirus 229E superfamily 1 helicase has RNA and DNA duplex-unwinding activities with 5'-to-3' polarity. RNA. 2000; 6(7):1056-68. PMC: 1369980. DOI: 10.1017/s1355838200000728. View

4.
Crotty S, Maag D, Arnold J, Zhong W, Lau J, Hong Z . The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 2000; 6(12):1375-9. DOI: 10.1038/82191. View

5.
Zuo Y, Deutscher M . Exoribonuclease superfamilies: structural analysis and phylogenetic distribution. Nucleic Acids Res. 2001; 29(5):1017-26. PMC: 56904. DOI: 10.1093/nar/29.5.1017. View